A B S T R A C T The specificities of anti-RNA antibodies of diverse origin were studied by inhibition of the binding of radioative polyinosinic polycytidylic acid. The antibodies were from human patients with systemic lupus erythematosus (SLE), older NZB/NZW F1 mice who have SLE, and young NZB/NZW F1 mice immunized with either synthetic or viral double-stranded (ds) RNA. The inhibitors were two viral ds and two synthetic ds RNAs, ribosomal RNA and transfer RNA. The human sera were more heterogeneous than the mouse lupus sera, and had greatest specificity for reovirus RNA. The mouse lupus sera were more homogeneous and, in general, were inhibited efficiently by all four ds RNAs. Sera from mice immunized with synthetic RNA reacted poorly with viral RNA, whereas sera from mice immunized with viral RNA reacted with all four ds RNAs and resembled the lupus sera. These results suggest a role for viruses in the induction of anti-RNA antibodies, and are compatible with the concept that virus infection as well as excessive antibody responses are involved in the pathogenesis of SLE.
INTRODUCTION
Antibodies to double-stranded (ds)' DNA and RNA occur with great frequency in patients with systemic lupus erythematosus (SLE) and rarely in patients with other connective tissue disorders (1) (2) (3) . These antibodies are also present in New Zealand mice, particularly the NZB/ NZW F1 hybrid (B/W) which is an animal model for human SLE (1) . Other antibodies reacting with singlestranded DNA and a variety of cellular components are found in lupus and in other connective tissue diseases.
It is possible to induce anti-RNA antibodies in normal strains of mice immunized with synthetic polyribonucleotides given in adjuvant but without protein carrier (4) . Rabbits can be immunized with RNA complexed to protein carrier (5) . Experimental immunization with native DNA has so far been unsuccessful, even when the DNA is complexed to protein.
This study attempts to explore the mechanism underlying the spontaneous formation of these anti-nucleic acid antibodies in SLE. Some clues to this problem can be sought in the antibody molecules themselves, since their specificity should reflect in mirror image the nature of the immunizing antigen.
We have studied this question using four different sets of anti-RNA antibodies. One set of antibodies came from patients with SLE and a second from older B/W mice with lupus. Both represent antibodies induced by naturally occurring immunogens during the course of disease. A third set of antibodies was prepared by immunizing young B/W mice with either polyinosinic* polycytidylic acid (rI rC) or polyadenylic polyuridylic acid (rA.rU). A fourth was prepared by immunizing young B/W mice with a viral ds RNA prepared from a fungal phage (mycophage). These latter two groups represent antibodies induced artificially by immunization.
The specificity of these four different sets of antibodies was studied by inhibiting the binding of radioactive RNA with various nucleic acids. Each of the four groups showed distinctive patterns of inhibition.
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The Journal of Clinical Investigation Volume 50 1971 METHODS Materials. Sera were obtained from human lupus patients and from NZB/NZW F1 mice. The mice were bled by orbital sinus puncture. Sera were stored frozen at -20'C until studied. Heating of sera at 560C for 30 min had no effect on RNA binding and this step was omitted.
Nonradioactive rI rC and rA rU, and "C-rI rC were purchased from Miles Laboratories, Inc., Elkhart, Ind. 'C-KB cell DNA was prepared as previously described (6) . Ribosomal RNA was prepared by phenol extraction from rat liver (7) . Rat liver, E. coli, and yeast transfer RNAs were given to us by Dr. Bernard Weinstein of Columbia University, New York. Reovirus ds RNA was a gift from Dr. George Acs of the Institute for Muscle Disease and mycophage ds RNA (from Penicillium chrysogenum) was a gift from Dr. K. W. Buck of the Imperial College of Science and Technology, London, England.
Immunization. 4-6-wk old female NZB/NZW F1 mice were immunized intraperitoneally with three different ds RNAs. Equal volumes of rI rC, rA-rU, or mycophage RNA (1 mg/ml) and complete Freund's adjuvant were emulsified and 0.3 ml of the mixture injected. The mice were bled 2 wk later for assay of anti-RNA antibodies.
Binding assay. The ammonium sulfate precipitation assay was used throughout. Serial dilutions of sera were incubated with 80 m/ug of`4C-rI -rC and the antigen-antibody complex precipitated by 35% ammonium sulfate as previously described (1) . Dilutions of sera that gave 40-86% binding were then used for inhibition studies. This guaranteed that reactions were taking place on the linear part of the binding curve. For the human lupus sera, the mean binding was 62% (range 40-86); for the mouse lupus sera, the mean binding was 64% (range 41-86).
To detect antibodies to DNA, 50 m~ug of "C-KB cell DNA was used and precipitation was achieved with 50% ammonium sulfate (1) .
Inhibition assay. The appropriate dilution of serum was then incubated with or without one of the RNA inhibitors in borate buffer (pH 8.0) for 30 min at 37°C. In some experiments a 4-fold excess of inhibitor was used and the results were expressed as per cent inhibition. In the majority of experiments, four different concentrations of inhibitor (varying from 30 to 6000 m/ug) were used. 80 m/ug of`4C-rI .rC was added and a second 30 min incubation at 37°C followed. After overnight incubation at 4°C, an equal volume (0.1 ml) of ammonium sulfate was added to bring the final concentration to 35%. The tubes were kept at 4°C for 1 hr before separation of precipitate and supernatant fractions by centrifugation at 11,500 g for 7.5 mins. Each fraction was placed in Bray's solution and radioactivity determined in a Nuclear Chicago liquid scintillation counter (Nuclear Chicago Corp., Des Plaines, Ill.) The per cent of bound antigen was determined for each point and from that the per cent of inhibition of binding for each concentration of inhibitor was calculated. The per cent inhibition was plotted against the logio of the inhibitor concentration and that concentration giving 50% inhibition was calculated. This concentration was called the Iso for the serum under study.
Absorption. A human lupus serum was divided into four 1 ml portions. A slight excess of antigen (either calf thymus DNA, rI-rC, or rA-rU) was added to each of three samples while the fourth was carried through the procedure as a control. After incubation at 37°C for 1 hr and at 4°C for 3 days, the precipitates were removed by centrifugation at 11,500 g. Each supernatant was again absorbed with the same antigen for 4 days at 4°C. The supernatants recovered after a second centrifugation were assayed for "C-rI-rC binding.
RESULTS
Antibodies to ds RNA and to ds DNA are predominantly different molecular populations. Six human lupus sera containing both antibody activities were studied in a differential inhibition experiment. The binding of radioactive DNA by antibody was inhibited 82% by prior incubation with a 4-fold excess of nonradioactive DNA, but only 15% by prior incubation with rI * rC. Conversely, the binding of radioactive rI-rC was inhibited 57% by prior incubation with rI -rC and only 6% by DNA. The reduction of rID rC binding would have been even greater if viral ds RNA was used as the competitive inhibitor (vide infra).
One serum was absorbed with either rI rC or DNA in an attempt to remove the antibodies to ds RNA. Ab- Inhibition of Anti-RNA Antibodies in Lupus sorption with the synthetic ds RNA reduced the binding of "4C-rI rC 70%, whereas absorption with DNA resulted in only a 16% reduction in 1"C rI * rC binding. The binding of "4C-rI rC by nine human lupus sera was studied by competitive inhibition using a 4-fold excess of two synthetic ds RNAs (rI. rC and rA rU) and six naturally occurring RNAs. Two were viral (reovirus and mycophage), one was ribosomal, and three were transfer RNAs of diverse origins. The ds viral RNAs showed the most complete inhibition (Table I ). In general, the synthetic ds RNAs were the second most efficient inhibitors, although three sera (HR, BB, ML) were inhibited as well by mammalian ribosomal RNA as by one of the synthetic RNAs. Ribosomal RNA is single-stranded whereas double-stranded regions occur in the structure of transfer RNA. Simple nucleotides, polyribonucleotides, nucleosides, or free bases failed to inhibit.
The comparative inhibition by viral and synthetic ds RNA was explored further in a study involving mouse as well as human antibodies to ds RNA. The NZB/ NZW F1 mice spontaneously develop SLE and produce antibodies that bind 14C-rI rC during the course of their disease. 16 sera from such mice spontaneously making antibodies to RNA were compared with 18 human lupus sera. Four inhibitors (reovirus and phage ds RNA, rI' rC, and rA-rU) were studied at several dilutions to permit a determination of the amount of inhibitor RNA that would result in a 50% reduction of '4C-rI rC binding (called the 15o). The data are presented in Tables   II and III . The per cent binding by uninhibited serum is included for comparison. In general, the mouse antibodies were well inhibited by all four ds RNAs at the concentrations used. An Iso could be determined for virtually each inhibitor and each serum. The human antibodies were much more heterogeneous and more difficult to inhibit. The median Lo was higher than for the mouse sera, ranging from 750 to > 6000 myg. Reovirus RNA was the best inhibitor, and an-Iso could be determined for 72% of the sera. However, even at a great excess of inhibitor, 45% or more of the sera were not inhibited 50% by the three other ds RNAs. Only three human sera (LN, AB, DD) resembled the mice in that all four inhibitors competed efficiently to prevent binding of 4C-rI * rC. Table IV . Mice immunized with phage RNA (group 1) produced antibodies that were inhibited well by both naturally occurring and synthetic ds RNAs. An Iso could be determined for most sera. In this respect they had properties that seemed intermediate between those of antibodies appearing in mice and humans afflicted with lupus (groups 4 and 5). By contrast, most mice immunized with either rI*rC (group 2) or rA rU (group 3) produced antibodies that were inhibited efficiently only by synthetic ds RNA. For example, the mean inhibition by reovirus RNA was 20% for the 20 such sera failing to give an Is0, i.e., 10 sera from group 2 and 10 sera from group 3 in Table IV . In spite of the genetically homogeneous background of the mice and the immunologic cross-reactivity of ds RNAs, the specificities of antibodies produced in response to viral ds RNA are remarkably different from those induced by synthetic ds RNA. DISCUSSION 50% or more of patients with SLE and B/W mice have antibodies to ds DNA or RNA as detected by the ammonium sulfate precipitation method. The present study was designed to investigate the specificity of the anti-RNA antibodies and indirectly the nature of the immunogenic RNA.
These antibodies are inhibited relatively poorly by ribosomal and transfer RNA, suggesting that these mammalian RNAs may not be the naturally occurring immunogens. The anti-RNA antibodies react better with two viral and two synthetic ds RNAs, although individual differences exist. The mouse sera are more homogeneous than the human, suggesting a similarity of antibody specificity. This can reflect either a uniform genetic background, a common immunologic stimulus, or both.
The New Zealand mice are highly inbred and therefore of a more similar genetic composition than the outbred human lupus population. Therefore, it was necessary to show that the specificity of anti-RNA antibodies Previous studies with human lupus anti-RNA antibodies showed precipitation with viral as well as synthetic ds RNA but not with ribosomal or transfer RNA (2). Stollar found that rabbit anti-RNA antibodies and human lupus anti-DNA antibodies cross-reacted with RNA: DNA hybrids, although antibodies raised against the hybrids did not react with ds RNA or DNA (15) . Another study showed that rabbit antibodies to rA -rU precipitated with some DNAs (5).
The h5o for any serum and inhibitor is a complex function dependent upon the binding characteristics of the antibody for rJ * rC and the molecular configuration of the inhibitor RNA. In preliminary experiments we observed in the direct binding assay that antigen-binding curves, i.e. per cent of "C-rI . rC bound vs. logs of antiserum dilution, varied in slope. A relatively steep curve correlated with greater strength of binding and a low Lo in subsequent inhibition studies. A serum giving a steep curve was inhibited even when the nonradioactive RNA was added after the 'C-rI * rC. A relatively flat curve correlated with weaker binding and such sera were poorly inhibited giving a high Ih. Such sera were not inhibited when the nonradioactive RNA was added after the "C-rI -rC. A serum with high capacity for rI-rC but a flat binding curve might produce the occasionally noted paradox of 'C-rI .rC binding with poor inhibition by rI rC.
The efficient inhibition by reovirus RNA is all the more remarkable because sera were selected on the basis of rI -rC binding. Despite the selection against reovirus RNA, the latter was a very good inhibitor. An even greater specificity for virus RNA might be demonstrated when radioactive viral RNA becomes available.
